Can suicide risk be detected in the blood?

Published On 2019-09-08 13:50 GMT   |   Update On 2019-09-08 13:50 GMT

Researchers at Brundin, Achtyes, and Mann are in process of developing a biomarker for diagnosis of suicide.


A new clinical study aims to identify blood-based biomarkers for suicide risk, laying the foundation for a test that could help physicians identify people who are likely to self-harm and allow for earlier, life-saving intervention.


The project is the first longitudinal study of its kind and is a collaboration between Van Andel Institute’s Lena Brundin, M.D., Ph.D., Pine Rest Christian Mental Health Services’ Eric Achtyes, M.D., M.S., and Columbia University Department of Psychiatry’s J. John Mann, M.D. It is supported by a newly awarded five-year, $3.6 million grant from the National Institute of Mental Health of the National Institutes of Health.


“Suicide is a leading cause of death in the U.S. and, unfortunately, rates continue to increase,” Brundin said. “Suicidal ideation is more than mental — there are measurable biological contributors such as byproducts of chronic inflammation that influence a person’s likelihood for self-harm. Leveraging these markers could hold the key to helping people before it is too late.”


Inflammation is the body’s reaction to harmful stimuli, such as infection, injury or chronic disease. It is marked by a cascade of white blood cells, which produce chemicals that help resolve the problem and jumpstart the healing process. However, inflammation is a short-term fix; when it continues past the point it is needed, it can have devastating consequences.


For example, growing evidence — including findings from the labs of Brundin, Achtyes, and Mann — suggest that sustained inflammation may cause a toxic imbalance that alters brain chemistry and elevates suicide risk. In addition to searching for markers, the team will work to identify the inflammatory mechanisms that give rise to depressive and suicidal symptoms with the goal of developing ways to stop them.


During the five-year study, which is slated to begin enrolling at Pine Rest in October, 160 people will be followed for one year and provide blood specimens along with clinical information. Participants will be selected from those who are admitted to the inpatient hospital or the outpatient clinics and divided into two groups — those who are depressed with suicidal thoughts or behaviors and those who present with depression alone.


“Clinicians are looking for tools to help them identify individuals who are at highest risk for suicide among those who are depressed,” Achtyes said. “We are hopeful this study will help us develop these tools to better understand who is at imminent risk.”


In tandem with the clinical study, the team will search for inflammatory markers in brain tissue samples from people who have died by suicide. The samples are housed at the New York State Psychiatric Institute Brain Bank at Columbia University.


“Suicidal behavior often occurs during an acute crisis or stress affecting a person with psychiatric illness,” Mann said. “Similarly, inflammation can be triggered by life stress or acute psychiatric illness and can alter brain function, which may result in depression, fatigue, and irritability. In some cases, this can lead to a suicide attempt. We plan to track stress and inflammation in psychiatric patients and link fluctuations in their levels to suicidal thoughts and actions in order to find ways to help prevent suicidal behavior.”


In 2017, suicide was the 10th leading cause of death overall in the U.S. and the second leading cause of death among people ages 10–34. From 2001 to 2017, suicide rates in the U.S. climbed 31 percent, from 10.7 to 14 people per 100,000, according to the National Institute of Mental Health.


The confidential National Suicide Prevention Lifeline is free and available 24/7 at 1-800-273-TALK (8255).


The research reported in this publication is supported by the National Institute of Mental Health of the National Institutes of Health under award no. 1R01MH118221 (Brundin, Achtyes, Mann). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News